Citigroup
ELOS

Citigroup’s Syneron Medical Ltd ELOS Stock Holding History

Citigroup’s Portfolio ELOS Stock Details ELOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-10,079
Closed -$106K – 7639
2017
Q1 		$106K Buy
+10,079
New +$97.5K ﹤0.01% 5170
2016
Q2 		– Sell
-11
Closed – – 7727
2016
Q1 		$0 Buy
+11
New +$79 ﹤0.01% 8025
2015
Q3 		– Sell
-98
Closed -$1K – 8051
2015
Q2 		$1K Buy
98
+7
+8% +$82 ﹤0.01% 7420
2015
Q1 		$1K Sell
91
-137
-60% -$1.52K ﹤0.01% 7126
2014
Q4 		$2K Buy
228
+116
+104% +$1.12K ﹤0.01% 6902
2014
Q3 		$1K Buy
+112
New +$1.14K ﹤0.01% 6990
2014
Q2 		– Sell
-268
Closed -$3K – 7473
2014
Q1 		$3K Buy
+268
New +$3.17K ﹤0.01% 6741
2013
Q4 		– Sell
-1,500
Closed -$13K – 7266
2013
Q3 		$13K Hold
1,500
– – ﹤0.01% 6120
2013
Q2 		$13K Buy
+1,500
New +$13.4K ﹤0.01% 6008

Other funds holding ELOS

BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
GLAM
Gardner Lewis Asset Management Chadds Ford, Pennsylvania $462M AUM 65.29% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
DGHMC
Dalton, Greiner, Hartman, Maher & Co New York $126M AUM 92.88% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Citigroup's ELOS Position: Q2 2017 in Review

Citigroup sold out of Syneron Medical Ltd (ELOS) in Q2 2017, closing a stake of 10,079 shares — an estimated $106K sold.

Citigroup first reported a position in ELOS in Q2 2013 and held it in 9 quarters. The position peaked at $106K in Q1 2017. 79 funds tracked by Wall St. Rank hold ELOS as of Q2 2017.

  • Citigroup reported no remaining Syneron Medical Ltd position as of Q2 2017 after selling out during the quarter.
  • Citigroup sold 10,079 Syneron Medical Ltd shares in Q2 2017, an estimated $106K.
  • Citigroup first reported a position in Syneron Medical Ltd in Q2 2013 and held it in 9 quarters.
  • Citigroup's Syneron Medical Ltd position peaked at $106K in Q1 2017.
  • 79 funds tracked by Wall St. Rank held Syneron Medical Ltd as of Q2 2017.

Based on Citigroup's 13F filing for Q2 2017, filed 11 Aug 2017.